Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Feb;43(2):201–209. doi: 10.1038/bjc.1981.29

Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.

R Verloes, G Atassi, P Dumont, L Kanarek
PMCID: PMC2010509  PMID: 7470382

Abstract

The experiments aimed at evaluating the optimal parameters in the chemo-immunotherapeutic treatment of the L1210 lymphoid leukaemia grafted to [female BALB/c (H2d) X male DBA/2 (H2d)]F1 hybrid mice, hereafter referred to as CDF1 mice. In vitro irradiation of leukaemic ascites cells by X- or gamma-rays and subsequent inoculation in mice showed that optimum immunogenicity is radiation dose-dependent. Grafting mice with 10(7) leukaemic ascites cells irradiated at optimum dose (80 GyX- or gamma-rays) delays mortality of the animals when challenged later with untreated L1210 cells, but is unable to cure mice. By contrast, specific immunoprophylaxis induced by Micrococcus, complement-triggering polysaccharides or BCG and irradiated leukaemic cells was able to protect mice against grafts of 10(4) L1210 cells. The i.p. route was notably superior to the i.v. route. When mice bearing advanced L1210 tumour were treated by chemotherapy (12 mg/kg of BCNU) on Day 6.5 after grafting 10(4) L1210 cells and subsequently treated by immunotherapy, a very high percentage (up to 90%) of mice with 10(8) leukaemic cells could be cured by repeated 1mg injections of bacterium or polysaccharide, and challenge with irradiated leukaemic cells was unnecessary. Because of the high cure rate obtained, the very regular response pattern and the non-pathogenicity, the bacterium Micrococcus lysodeikticus would seem a promising new candidate for chemo-immunotherapeutic antitumour strategies.

Full text

PDF
201

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bianco C., Eden A., Cohn Z. A. The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med. 1976 Dec 1;144(6):1531–1544. doi: 10.1084/jem.144.6.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cantrell J. L., Killion J. J., Kollmorgen G. M. Correlations between humoral immunity and successful chemotherapy-immunotherapy. Cancer Res. 1976 Sep;36(9 PT1):3051–3057. [PubMed] [Google Scholar]
  3. De Baetselier P., Grooten J., Van Der Winkel M., Hamers R. Probing lymphoid systems with anti-micrococcus antibodies. I. Effect on lymphocyte response to mitogens in vitro [proceedings]. Arch Int Physiol Biochim. 1977 Feb;85(1):161–163. [PubMed] [Google Scholar]
  4. GLYNN J. P., HUMPHREYS S. R., TRIVERS G., BIANCO A. R., GOLDIN A. STUDIES ON IMMUNITY TO LEUKEMIA L1210 IN MICE. Cancer Res. 1963 Aug;23:1008–1015. [PubMed] [Google Scholar]
  5. Huget R. P., Flad H. D., Opitz H. G. Suppression of in vitro primary immune response by L1210 cells and their culture supernatant: evidence for cytotoxic effects. Cell Immunol. 1977 Mar 1;29(1):210–215. doi: 10.1016/0008-8749(77)90290-8. [DOI] [PubMed] [Google Scholar]
  6. Hunt J. S., Silverstein M. J., Sparks F. C., Haskell C. M., Pilch Y. H., Morton D. L. Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet. 1973 Oct 13;2(7833):820–821. doi: 10.1016/s0140-6736(73)90860-x. [DOI] [PubMed] [Google Scholar]
  7. Kataoka T., Kobayashi H., Sakurai Y. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents. Cancer Res. 1978 May;38(5):1202–1207. [PubMed] [Google Scholar]
  8. Mansell P. W. Letter: Reactions to BCG. JAMA. 1973 Dec 24;226(13):1570–1571. doi: 10.1001/jama.1973.03230130058031. [DOI] [PubMed] [Google Scholar]
  9. Mathé G., Halle-Pannenko O., Bourut C. Interspersion of cyclophosphamide and BCG in the treatment of L1210 leukaemia and Lewis tumour. Eur J Cancer. 1977 Oct;13(10):1095–1098. doi: 10.1016/0014-2964(77)90006-8. [DOI] [PubMed] [Google Scholar]
  10. Schein P. S., Bull J. M., Doukas D., Hoth D. Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1978 Feb;38(2):257–260. [PubMed] [Google Scholar]
  11. Schorlemmer H. U., Davies P., Allison A. C. Ability of activated complement components to induce lysosomal enzyme release from macrophages. Nature. 1976 May 6;261(5555):48–49. doi: 10.1038/261048a0. [DOI] [PubMed] [Google Scholar]
  12. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]
  13. Verloes R., Atassi G., Dumont P., Kanarek L. Influence of micrococcus, BCG and related polysaccharides on the proliferation of the L1210 leukaemia. Br J Cancer. 1978 Nov;38(5):599–605. doi: 10.1038/bjc.1978.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Verloes R., Atassi G., Kanarek L. Comparison between the in vitro interaction of lectins (PHA and con A) and antimicrococcus antibodies on normal and malignant cells. Eur J Cancer. 1979 Dec;15(12):1439–1448. doi: 10.1016/0014-2964(79)90022-7. [DOI] [PubMed] [Google Scholar]
  15. Verloes R., De Ridder M., Kanarek L. Biochemical properties that accompany the production of homogeneous antibody response: a general mechanism hypothesis [proceedings]. Biochem Soc Trans. 1977;5(4):1158–1159. doi: 10.1042/bst0051158. [DOI] [PubMed] [Google Scholar]
  16. Verloes R., Kanarek L., Atassi G. Antitumour immunoprotection by an immunobacterial lectin approach. Eur J Cancer. 1976 Nov;12(11):877–888. doi: 10.1016/0014-2964(76)90005-0. [DOI] [PubMed] [Google Scholar]
  17. Verloes R., Kanarek L. Interactions of the lectins PHA, ConA and antimicrosoccus with blood cells of different species and Erhlich carcinoma cells. Arch Int Physiol Biochim. 1976 Apr;84(2):418–420. [PubMed] [Google Scholar]
  18. Verloes R., Machtelinckx V., Theunissen J., Kanarek L. The immune response of micr to Micrococcus lysodeikticus: evidence for serum-mediated immunoregulation [proceedings]. Biochem Soc Trans. 1977;5(4):1156–1157. doi: 10.1042/bst0051156. [DOI] [PubMed] [Google Scholar]
  19. Ward P. A. A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med. 1967 Aug 1;126(2):189–206. doi: 10.1084/jem.126.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wikler M. Isolation and characterization of homogenous rabbit antibodies to Micrococcus lysodeikticus with specificity to the peptidoglycan and to the glucose-N-acetylaminomannuronic acid polymer. Z Immunitatsforsch Exp Klin Immunol. 1975 Jul;149(2-4):193–200. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES